Study In Patients With Dyslipidaemia

GlaxoSmithKline (GSK)

Status and phase: Completed; Phase 2

Conditions: Metabolic Syndrome X

Treatments: Drug: GW677954

Study type: Interventional

Funder types: Industry

Identifiers

NCT00264667

ADG103440

Details and patient eligibility

About

Study in patients with dyslipidaemia.

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Waist circumference =102cm (men) or =88cm (women) at visit 1.
• Fasting plasma HDL C =40mg/dL (1.03mmol/L) (men) or =50mg/dL (1.29mmol/L) (women) at Screening Visit 1.
• Fasting TGs =150mg/dL (1.69mmol/L) and =800mg/dL (8.96mmol/L) at Screening Visit 1.
• Subjects whose plasma LDL C concentration does not require treatment according to the NCEP ATP III guidelines at Screening Visit 1.

Exclusion criteria

• History of diabetes
• History of cardiovascular disease
• Diagnosis of genetic lipid disorders
• History of muscle pain
• History of cancer

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind